Skip to main content
PharmaBlock Sciences (Nanjing), Inc. logo

PharmaBlock Sciences (Nanjing), Inc. — Investor Relations & Filings

Ticker · 300725 ISIN · CNE1000035K5 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,618 across all filing types
Latest filing 2023-04-21 Notice of Dividend Amou…
Country CN China
Listing Shenzhen Stock Exchange 300725

About PharmaBlock Sciences (Nanjing), Inc.

https://www.pharmablock.com

PharmaBlock Sciences (Nanjing), Inc. specializes in the design and manufacture of innovative building blocks and provides integrated chemistry services for drug discovery and development. The company offers a comprehensive portfolio of structurally diverse scaffolds and intermediates used to enhance the efficiency of medicinal chemistry. Its core capabilities include process research and development, scale-up production, and commercial-scale manufacturing under CDMO frameworks. By utilizing advanced chemical technologies and a vast library of unique chemical entities, the company supports global biotechnology and pharmaceutical organizations in streamlining their research pipelines and optimizing the transition from discovery to clinical development and commercialization.

Recent filings

Filing Released Lang Actions
关于公司2022年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2022 annual profit distribution plan of the company. It includes details about the net profit, proposed cash dividend per share, and the need for shareholder approval at the annual general meeting. The document is relatively short (1295 characters) and focuses on the dividend distribution proposal rather than presenting full financial statements or comprehensive annual report content. It is not a full Annual Report (10-K) or Interim Report (IR), nor is it a Dividend Notice with payment dates. Instead, it is a formal announcement of the profit distribution plan, which aligns with the category of Notice of Dividend Amount (DIV).
2023-04-21 Chinese
2023年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "南京药石科技股份有限公司2023 年第一季度报告" which translates to "Nanjing Medicine Stone Technology Co., Ltd. 2023 First Quarter Report." It contains detailed financial data including balance sheets, income statements, cash flow statements, and shareholder information for the first quarter of 2023. The document explicitly states it is a quarterly report and includes comprehensive financial statements and analysis for the quarter. It also mentions that the report is unaudited. The length of the document (13,536 characters) and the detailed financial content confirm it is a full interim/quarterly financial report rather than a brief announcement or summary. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q1 2023
2023-04-21 Chinese
2022年年度财务报告
Annual Report Classification · 100% confidence The document is titled as the "2022 Annual Financial Report" of 南京药石科技股份有限公司, indicating it is a full annual report. It contains detailed audited financial statements including consolidated and parent company balance sheets, income statements, cash flow statements, and notes. There is a comprehensive audit report with an unqualified opinion from a registered accounting firm dated April 21, 2023. The document includes extensive financial data for the full fiscal year 2022, management responsibilities, and auditor responsibilities. The length is substantial (15,000 characters), and it contains the full financial report, not just an announcement or certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2022
2023-04-21 Chinese
华泰联合证券有限责任公司关于南京药石科技股份有限公司部分募投项目变更暨新增募集资金投资项目的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from Huatai United Securities Co., Ltd., acting as the sponsor for Nanjing Yaoshi Technology Co., Ltd. It discusses changes in the use of funds raised from specific stock issuance and convertible bonds, including project descriptions, investment amounts, usage status, and approvals from the board, independent directors, and supervisory board. The document includes financial data, project feasibility, and regulatory compliance details. It is a formal verification and opinion report related to changes in fundraising project usage, not a full annual or interim financial report, earnings release, or capital update. It is not a simple announcement but a detailed verification opinion on fundraising project changes. This fits the category of Capital/Financing Update (CAP), as it concerns updates on fundraising and capital use changes with detailed financial and project information.
2023-04-21 Chinese
华泰联合证券有限责任公司关于南京药石科技股份有限公司2023年度部分募投项目延期的核查意见
Regulatory Filings Classification · 95% confidence The document is a verification opinion from Huatai United Securities Co., Ltd. regarding the delay of certain fundraising investment projects of Nanjing Yaoshi Technology Co., Ltd. It discusses the 2020 private placement of shares and the use of the raised funds, specifically the delay in the 'Nanjing R&D Center Upgrade Project'. The document includes detailed project investment amounts, progress, reasons for delay, and the impact on the company. It also contains the board of directors' approval, independent directors' opinions, and supervisory board review. The document is a formal verification and opinion letter related to the use and delay of funds raised in a specific financing event, not a full financial report or earnings release. It is not an announcement of a report publication but a regulatory compliance verification document. Therefore, it fits best under Regulatory Filings (RNS) as it is a compliance and verification filing related to fundraising project delays and does not contain financial statements or earnings data itself.
2023-04-21 Chinese
2022年度监事会工作报告
Management Reports Classification · 95% confidence The document is titled as the "2022年度监事会工作报告" which translates to "2022 Supervisory Board Work Report". It details the supervisory board's activities, meetings, opinions on company operations, financial status, internal controls, and other governance matters for the year 2022. It includes detailed oversight and supervisory opinions rather than just announcements or summaries. The document length is 5517 characters, which is sufficient to contain substantive content rather than a brief announcement. The content focuses on supervisory board work and oversight rather than full financial statements or audit opinions alone. This aligns with a Management Reports (MDA) filing, which includes management's detailed explanation of financial results, business trends, and outlook, including supervisory board reports. It is not an Annual Report (10-K) or Audit Report (AR) because it does not contain full financial statements or standalone audit opinions. It is not a Regulatory Filing (RNS) or Report Publication Announcement (RPA) because it contains substantive supervisory content rather than just a notice or certification. Therefore, the best classification is Management Reports (MDA).
2023-04-21 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.